Chinese hamster ovary (CHO) cell line is the major host cell for the manufacturing of pharmaceutical biologics. The proprietary CHO cell line with intellectual property is highly required in the biotech companies for biologics product production. We developed a high yield CHO cell expression system, named CHO-C platform, including a proprietary CHO cell line and proprietary expression plasmids. The mAb productivity in the CHO-C platform was about 1.5-2 fold better than that in the CHO-S/pCHO1.0 system. The stability of the CHO-C cell can be maintained over 120 generations. In addition, the quality of mAb produced from CHO-C cells was comparable to benchmark control. Altogether, the CHO-C platform is a competitive and valuable mammalian expression system for biologics production.

DCBCO1901 with a novel chemical structure exhibits highly potent and selective inhibitory activity against FLT3 as well as its mutants. DCBCO1901 exhibits selective cytotoxicity and effectively suppresses the intracellular FLT3 signaling in AML cell lines harboring the FLT3 mutant. Once-daily oral administration of DCBCO1901 completely suppresses FLT3-ITD mutant tumor growth in a xenograft model and PDX model. Hence, DCBCO1901 can be a precision medicine for treating cancer patients with FLT3 mutation.

1. Pharmaceutical Synthesis Platform Technology

2. Pharmaceutical process development

3. In vitro biological activity screening for Anticancer drugs

4. Safety Pharmacology

5. In vitro activity mechanism test

6. Caco-2 permeability assay

1. Protein Drug Discovery and Development

2. Protein Drug Characterization

3. Protein Drug Functional Study

1. Pharmacology Study

2. Drug Analysis & Formulation